This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Click here for Eliquis® (apixaban) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Eliquis® (apixaban)

ELIQUIS® (apixaban) is an oral, direct factor Xa inhibitor indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II)
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
  • Prevention of recurrent DVT and PE in adults
  • Prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery


Eliquis is co-promoted with Bristol Myers-Squibb.

Learn MoreLoadingReference:Eliquis (apixaban) Summary of Product Characteristics Medicines List - Search PIL, SPC & EDM | Medicines.ieAdverse events should be reported. Reporting forms and information
can be found at: Ireland - via HPRA Pharmacovigilance at  www.hpra.ie

Adverse events should also be reported to Bristol-Myers Squibb via
 [email protected] or 1 800 749 749 (Ireland)

Legal Category: S1B
Further Information is available upon request.

PP-ELI-IRL-0598. January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No